These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 21887833)

  • 21. Inhibition of cytotoxicity and amyloid fibril formation by a D-amino acid peptide that specifically binds to Alzheimer's disease amyloid peptide.
    Wiesehan K; Stöhr J; Nagel-Steger L; van Groen T; Riesner D; Willbold D
    Protein Eng Des Sel; 2008 Apr; 21(4):241-6. PubMed ID: 18252750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Requirement of aggregation propensity of Alzheimer amyloid peptides for neuronal cell surface binding.
    Bateman DA; McLaurin J; Chakrabartty A
    BMC Neurosci; 2007 May; 8():29. PubMed ID: 17475015
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biflavonoids are superior to monoflavonoids in inhibiting amyloid-β toxicity and fibrillogenesis via accumulation of nontoxic oligomer-like structures.
    Thapa A; Woo ER; Chi EY; Sharoar MG; Jin HG; Shin SY; Park IS
    Biochemistry; 2011 Apr; 50(13):2445-55. PubMed ID: 21322641
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evidence of fibril-like β-sheet structures in a neurotoxic amyloid intermediate of Alzheimer's β-amyloid.
    Chimon S; Shaibat MA; Jones CR; Calero DC; Aizezi B; Ishii Y
    Nat Struct Mol Biol; 2007 Dec; 14(12):1157-64. PubMed ID: 18059284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. N-Terminal pyroglutamate formation of Aβ38 and Aβ40 enforces oligomer formation and potency to disrupt hippocampal long-term potentiation.
    Schlenzig D; Rönicke R; Cynis H; Ludwig HH; Scheel E; Reymann K; Saido T; Hause G; Schilling S; Demuth HU
    J Neurochem; 2012 Jun; 121(5):774-84. PubMed ID: 22375951
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Formation of toxic fibrils of Alzheimer's amyloid beta-protein-(1-40) by monosialoganglioside GM1, a neuronal membrane component.
    Okada T; Wakabayashi M; Ikeda K; Matsuzaki K
    J Mol Biol; 2007 Aug; 371(2):481-9. PubMed ID: 17582434
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Investigation on the influence of (Z)-3-(2-(3-chlorophenyl)hydrazono)-5,6-dihydroxyindolin-2-one (PT2) on β-amyloid(1-40) aggregation and toxicity.
    Catto M; Arnesano F; Palazzo G; De Stradis A; Calò V; Losacco M; Purgatorio R; Campagna F
    Arch Biochem Biophys; 2014 Oct; 560():73-82. PubMed ID: 25051344
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Light-controlled toxicity of engineered amyloid β-peptides.
    Hoppmann C; Barucker C; Lorenz D; Multhaup G; Beyermann M
    Chembiochem; 2012 Dec; 13(18):2657-60. PubMed ID: 23161824
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endogenous polyamines reduce the toxicity of soluble aβ peptide aggregates associated with Alzheimer's disease.
    Luo J; Mohammed I; Wärmländer SK; Hiruma Y; Gräslund A; Abrahams JP
    Biomacromolecules; 2014 Jun; 15(6):1985-91. PubMed ID: 24750033
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Location and conformation of amyloid β(25-35) peptide and its sequence-shuffled peptides within membranes: implications for aggregation and toxicity in PC12 cells.
    Tsai HH; Lee JB; Shih YC; Wan L; Shieh FK; Chen CY
    ChemMedChem; 2014 May; 9(5):1002-11. PubMed ID: 24729535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulation of in vitro Aβ1-40 aggregation mediated by small molecules.
    Kim HY; Kim Y; Han G; Kim DJ
    J Alzheimers Dis; 2010; 22(1):73-85. PubMed ID: 20847447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Versatile and efficient targeting using a single nanoparticulate platform: application to cancer and Alzheimer's disease.
    Le Droumaguet B; Nicolas J; Brambilla D; Mura S; Maksimenko A; De Kimpe L; Salvati E; Zona C; Airoldi C; Canovi M; Gobbi M; Magali N; La Ferla B; Nicotra F; Scheper W; Flores O; Masserini M; Andrieux K; Couvreur P
    ACS Nano; 2012 Jul; 6(7):5866-79. PubMed ID: 22725248
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protective effect of colostrinin on neuroblastoma cell survival is due to reduced aggregation of beta-amyloid.
    Schuster D; Rajendran A; Hui SW; Nicotera T; Srikrishnan T; Kruzel ML
    Neuropeptides; 2005 Aug; 39(4):419-26. PubMed ID: 15890402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Attenuation of the aggregation and neurotoxicity of amyloid-β peptides by catalytic photooxygenation.
    Taniguchi A; Sasaki D; Shiohara A; Iwatsubo T; Tomita T; Sohma Y; Kanai M
    Angew Chem Int Ed Engl; 2014 Jan; 53(5):1382-5. PubMed ID: 24339209
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dense shell glycodendrimers as potential nontoxic anti-amyloidogenic agents in Alzheimer's disease. Amyloid-dendrimer aggregates morphology and cell toxicity.
    Klementieva O; Benseny-Cases N; Gella A; Appelhans D; Voit B; Cladera J
    Biomacromolecules; 2011 Nov; 12(11):3903-9. PubMed ID: 21936579
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Zinc-induced dimerization of the amyloid-β metal-binding domain 1-16 is mediated by residues 11-14.
    Kozin SA; Mezentsev YV; Kulikova AA; Indeykina MI; Golovin AV; Ivanov AS; Tsvetkov PO; Makarov AA
    Mol Biosyst; 2011 Apr; 7(4):1053-5. PubMed ID: 21350790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Covalent modifier-type aggregation inhibitor of amyloid-β based on a cyclo-KLVFF motif.
    Kino R; Araya T; Arai T; Sohma Y; Kanai M
    Bioorg Med Chem Lett; 2015 Aug; 25(15):2972-5. PubMed ID: 26045033
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structure inducing ionic liquids-enhancement of alpha helicity in the Abeta(1-40) peptide from Alzheimer's disease.
    Debeljuh N; Barrow CJ; Henderson L; Byrne N
    Chem Commun (Camb); 2011 Jun; 47(22):6371-3. PubMed ID: 21547327
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aβ40(L17A/F19A) mutant diminishes the aggregation and neurotoxicity of Aβ40.
    Chen YR; Huang HB; Lo CJ; Wang CC; Su CL; Liu HT; Shiao MS; Lin TH; Chen YC
    Biochem Biophys Res Commun; 2011 Feb; 405(1):91-5. PubMed ID: 21216230
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Docosahexaenoic acid disrupts in vitro amyloid beta(1-40) fibrillation and concomitantly inhibits amyloid levels in cerebral cortex of Alzheimer's disease model rats.
    Hashimoto M; Shahdat HM; Yamashita S; Katakura M; Tanabe Y; Fujiwara H; Gamoh S; Miyazawa T; Arai H; Shimada T; Shido O
    J Neurochem; 2008 Dec; 107(6):1634-46. PubMed ID: 19014387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.